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Aim: To review the existing literature on the role and significance of intestinal transgluta-
minase 2 immunoglobulin A deposits (TG2 deposits) in patients with overt celiac disease
(CD), potential celiac disease (PCD), and other autoimmune or gluten-related conditions.
Methods: We conducted a systematic review of studies published in English, evaluating
presence and characteristics ofTG2 deposits in subjects with overt CD, PCD, gluten-related
diseases [dermatitis herpetiformis (DH), gluten-ataxia (GA)], autoimmune disorders (type-
1 diabetes), and other conditions. Studies were identified through a MEDLINE search
(1950–2013).
Results:Twenty-three studies were included in the review. Eleven studies were performed
in children. Overall TG2 deposits were present in 100% of adults with overt CD, while in
children prevalence ranged from 73.2 to 100%. Six studies with an established definition
of PCD were considered, prevalence of deposits ranging from 64.7 to 100%. A single
study followed-up PCD patients with repeated biopsies and identified presence of intesti-
nal deposits as the best marker to reveal progression toward villous atrophy. Two studies
investigated presence of deposits in DH, reporting prevalence between 63 and 79%. A sin-
gle study documented TG2 deposits in 100% of patients with GA. In children with type-1
diabetes (T1D), positivity of intestinal TG2 deposits ranged from 25 to 78%.
Conclusion: Transglutaminase 2 IgA deposits seem to be a constant feature in overt CD
patients and are frequently detectable in other gluten-related conditions (DH and GA). The
vast majority of PCD patients expressTG2 deposits at the intestinal level, but no sufficient
data are available to exactly define their prognostic role as a marker of evolution toward
overt CD. The frequent finding of TG2 deposits in the intestinal mucosa of patients with
T1D is an interesting observation deserving further evaluation.
Keywords: intestinal deposits, anti-tissue transglutaminase 2, celiac disease, potential celiac disease, dermatitis
herpetiformis, immunofluorescence
INTRODUCTION
Celiac disease (CD) is a chronic, immune-mediated enteropathy
triggered by the ingestion of gluten containing grains in geneti-
cally susceptible individuals, expressing the HLA-class 2 molecules
DQ2 or DQ8 (1). Clinical features vary greatly from asymptomatic
to classical or atypical presentation. Gluten-induced small-bowel
(SB) mucosal histological damage develops gradually, from lym-
phocytic infiltration of the epithelium to crypt hyperplasia and
further to villous atrophy (2). Histological confirmation of CD
can be challenging, as related to the quality of the biopsy spec-
imens (3) as well as the patchiness of the intestinal lesions (4).
Furthermore, similar SB mucosal abnormalities can be found in
other conditions such as giardiasis, viral infections, food allergy,
and autoimmune enteropathy.
Potential celiac disease (PCD) is a well-known condition, char-
acterized by a positive serology for CD with an architecturally
normal intestinal mucosa. Timing of progression toward classical
CD has not clearly been established in PCD, although a recent
study indicates that 30% of children with PCD left on a normal
diet develop villous atrophy within 4 years (5). In another study
performed in an at-risk population (first-degree relatives), 5% of
children with PCD developed overt CD within 2 years (6). In this
context, the search for a specific marker with a high prognostic
value is extremely appealing.
It was initially observed that the SB epithelial basement mem-
brane of CD patients contains specific deposits of immunoglob-
ulin A (IgA) (7), which were subsequently shown to be targeted
against extracellular transglutaminase 2 (TG2) (8). The original
technique to detect the presence of anti-TG2 IgA extracellular
deposits was introduced by Karponay-Szabò et al. (8). In the orig-
inal paper, authors accurately described a method of detecting the
co-localization of IgA deposits to TG2 by immunofluorescence
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FIGURE 1 | Small-bowel mucosal immunofluorescence staining of IgA (green) and transglutaminase-2 (red) and co-localization of IgA andTG2 in
yellow (arrow). In (A) a healthy control (no co-localization), in (B) a celiac patient with evidence of co-localization (arrow).
(Figures 1A,B). Based on this technique, they demonstrated pres-
ence of TG2 deposits in the intestinal mucosa of CD patients, PCD
patients, and subjects with dermatitis herpetiformis (DH).
So far several studies investigated the presence and the diag-
nostic role of TG2 IgA deposits in adults and children with either
overt CD or PCD. Intestinal deposits have been found to be a con-
stant feature in overt CD at diagnosis, while their intensity seems
to decrease on a gluten-free diet (GFD). Their role in PCD is less
clear, with some studies reporting a positive value in predicting
an intestinal damage. Furthermore intestinal deposits have been
described in other gluten-related disorders (DH and GA) and in
other autoimmune conditions, such as type-1 diabetes (T1D).
The determination of intestinal IgA deposits requires a fresh
biopsy sample to be stored in liquid nitrogen. It is a time con-
suming and expensive analysis, requiring an expert pathologist in
a specialized center. In consideration of such limitation and the
growing amount of data now available, the exact diagnostic role of
TG2 IgA deposits needs to be clarified. In this article, we provide a
systematic review of the existing literature on the diagnostic value
of intestinal deposits in CD and other gluten-related disorders,
aiming to answer the question whether this test can be used as an
early marker of disease progression in PCD.
MATERIALS AND METHODS
Before starting the search and review process, we defined the
review protocol, specifying the research question, inclusion and
exclusion criteria, search strategies, quality criteria, methods for
extracting related data, and statistical methods.
All studies (including cross-sectional, cohort, case–control, and
case-series) were considered eligible. Case reports, abstracts pre-
sented at meetings, and articles not published in English language
were excluded. Our search was focused on studies recruiting
patients of all ages with overt CD (associated with some degree
of villous atrophy at the SB biopsy), PCD, other gluten-related
diseases (gluten-sensitivity, GA, and DH), or other autoimmune
conditions [T1D, inflammatory bowel disease (IBD), autoimmune
thyroiditis], where the prevalence of intestinal anti-TG2 deposits
has been investigated, as a primary or secondary outcome. Overt
CD was defined according to the European Society of Pediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria
(9). PCD was defined as the positivity of serological markers
[anti-transglutaminase (TTG) and/or anti-endomysium (EMA)
antibodies] in presence of normal SB histology or minimal histo-
logical changes (Marsh 0–1). Studies giving ambiguous definitions
of PCD or considering PCD patients together with gluten-sensitive
or latent CD patients were not considered. No publication date or
publication status was imposed.
Relevant studies were identified through electronic databases
and scanning reference lists of eligible studies. Our search was
applied to the Medline database using PubMed by combining key
words for gluten-related disorders (CD, PCD, gluten intolerance,
gluten-sensitivity, GA, DH, autism, type-1 diabetes) and search
terms for intestinal deposits (intestinal deposits, IgA intestinal
deposits, anti-TG2 intestinal deposits, intestinal anti-tissue trans-
glutaminase, immunofluorescence). All studies were published
between 1950 (start of Medline) and December 2013. To ascer-
tain the validity of the eligible studies, the study design, the size,
and representativeness of the study population (i.e., the presence
of selection bias), the validity of outcomes (risk of confounding
or bias), and the quality of the statistical analysis were taken into
account.
The following informations were extracted from each study:
(1) characteristics of participants (number, age, diagnosis and
method of diagnosis, diet, length of diet); (2) serological mark-
ers [TTG, EMA, anti-gliadin antibodies (AGA) IgA and IgG]; (3)
prevalence, type, and features of intestinal deposits (anti-TG2,
anti-endomysium and AGA, intensity, submucosal or perivascular,
homogeneous or heterogeneous pattern).
RESULTS
STUDY CHARACTERISTICS
Overall we identified 25 eligible studies. Two of them were sub-
sequently excluded because prevalence of TG2 deposits was not
reported in the results in one and intestinal IgA deposits instead
of TG2 deposits were considered in the other (10, 11). We found
18 studies performed in celiac (overt and potential) patients, 9 of
them in pediatric groups. The remaining five studies were focused
on children with T1D and cerebral palsy and adult with GA, DH,
and gluten-sensitivity. Table 1 summarizes the features of the 23
selected studies.
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INTESTINAL DEPOSITS IN CD AT DIAGNOSIS
Ten studies investigating the presence of intestinal TG2 deposits in
patients with overt CD at diagnosis were identified and five were
performed in children (median age 6.5 years). The included stud-
ies involved a total of 863 CD patients, presence of deposits was
investigated only in 81.7% of cases. Results of the included studies
are summarized in Table 2.
Adults with untreated CD had TG2-targeted autoantibodies
deposition in the SB mucosa in 100% of cases (12–16), while
there was more variability in the pediatric population. By study-
ing 144 untreated CD children, Maglio and co-workers found that
TG2 IgA deposits had a sensitivity of 95.8% in diagnosis of CD
(17). The same authors reported a different prevalence of TG2
IgA deposits in younger children (<2 years of age) compared to
older groups. They found mucosal deposits in 73.2% of infants,
while the detection rate of serum EMA and/or anti-TG2 IgA was
82% in the same population. Conversely all children older than
2 years of age were positive for anti-TG2 IgA intestinal deposits
and had serum EMA and circulating TTG antibodies (18). Three
pediatric studies showed that deposits had a sensitivity of 100%
in untreated CD, confirming adult results (8, 19, 20). Further-
more intestinal TG2-targeted autoantibody deposits had the best
sensitivity values in detecting untreated CD with villous atrophy
comparing with other CD markers [increased density of villous tip
intraepithelial lymphocytes (IELs), increased density of γδ+ IELs,
increased density of CD3+ IELs, serum IGA-class autoantibodies]
in adult setting (12).
Overall, the mean value of specificity in all selected studies
(either adult patients or children) was 94.15% (range 82–100%).
Two studies found the intensity of these deposits significantly
higher in the celiac patients than in patients with PCD (17, 20).
Interestingly Salmi et al. found that in CD patients without serum
EMA, TG2 IgA were still deposited and detectable in the SB mucosa
in all cases (21). However, the same authors found that the inten-
sity of deposits did not correlate with the severity of the mucosal
lesion (21).
INTESTINAL DEPOSITS IN PCD
Several studies investigated the presence and features of intestinal
deposits in subjects with PCD, both in children and adults. Six
studies included a well-defined group of PCD patients, their main
characteristics, and results are summarized in Table 3.
In a total of 301 patients with PCD (289 children and 12 adults),
the prevalence of intestinal deposits ranged from 68 to 100%. The
intensity of deposits was described in four studies, all of them
showing that TG2 deposits were significantly less intense if com-
pared to subjects with overt CD (17, 20, 22, 23). Furthermore,
four studies detected a patchy distribution of intestinal deposits,
characterized by areas with strong staining, with weaker stain-
ing areas and areas completely negative (5, 17, 19, 22) Only one
prospective study, aiming to investigate the natural history of PCD,
followed-up children with PCD with repeated biopsy (5). Evalu-
ation of intestinal deposits was not the primary outcome of the
study and power calculation to address the research question was
not mentioned in the article. Comparing data from 12 patients
that developed villous atrophy and 27 who did not, authors found
that only the presence of intestinal deposits in the first biopsy was
Table 2 | Summary of the included studies evaluating the presence of
intestinalTG2 deposits in overt celiac disease (CD).
Reference
(first
author)
Age (years),
median
(range)
Overt CD
(n)
TG2 IgA
deposits:
prevalence
Diagnostic
value (%)
Korponay-
Szabo (8)
78 (4.4–32) 10 10/10 SE: 100
SP: 100
Salmi (12) 42 (16–81) 223 35/35 SE: 100
SP: 100
Koskinen
(14)
47 (4–79) 261 261/261 SE: 100
SP: 82
Koskinen
(15)
47 (28–68) 13 13/13 SE: 100
SP: 95.9
Kaukinen
(16)
47 (22–68) 18 6/6 SE: 100
SP: 100
Maglio
(17)
63 (6 months–
16 years)
144 138/144 SE: 95.8
SP: 87.9
Tosco (19) 7 12 12/12 SE: 100
SP: 80
Maglio
(18)
<2, 15 months <2 years: 56 <2 years: 41/56 SE: 73.2
>2, 7 years >2 years: 40 >2 years: 40/40 SE: 100
SP: ne
Kurppa
(20)
10 (1–15) 42 42/42 SE: 100
SP: ne
Salmi (21) 55 (20–79) 22 EMA− 18/18 SE: 100
40 (16–81) 22 EMA+ 17/17 SP: 100
SE, sensitivity; SP, specificity; ne, not evaluable (no control group).
different in the two groups, speculating that the presence of TG2
deposits could predict the evolution toward villous atrophy.
INTESTINAL DEPOSITS IN CD DURING FOLLOW-UP: PREVALENCE,
CORRELATION WITH OTHER CD MARKERS, AND RESPONSE TO
GLUTEN-CHALLENGE
Five studies specifically addressed the question whether and when
TG2 deposits disappear after establishing a GFD. Koskinen et al.
compared TG2 IgA deposits after short term (1 year) and long
term (2–41 years) GFD in a large cohort of pediatric and adult
CD patients. They found that deposits were still positive in 82 and
56%, respectively (14). These results were confirmed in another
study in adults, where 28 patients still showed presence of deposits
in 75% of cases after 1 year of GFD (24). Interestingly, CD mark-
ers were found to disappear in a sequential order during a GFD.
TG2 deposits disappeared after normalization of serum autoanti-
bodies, SB villous atrophy, and the densities of CD3+ IELs. The
increased density of γδ+ IELs was the only marker that disap-
peared later than the deposits (14). The same authors analyzed
27 adults with non-responsive CD and found that 6 patients with
poor adherence to the GFD had CD autoantibodies in both serum
and SB mucosa. In the remaining 21 non-responsive CD patients
with good adherence to the GFD, only 4 had serum autoantibodies
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Table 3 | Summary of the included studies evaluatingTG2 deposits in potential celiac disease (PCD).
Reference
(first author)
Age, median
(range)
PCD
(n)
PCD:
definition
TG2 IgA deposits:
prevalence
Diagnostic
value (%)
Intensity Results of follow-up studies and
comparison with other markers
Tosco (5) 6 years, 8 months
(18 months–
16 years)
106 TTG or
EMA+,
Marsh 0–1
66/102 SE: 64.7
SP: ne
– At 4 years follow-up, 30.8% develop
overt CD. TG2 deposits in the first
biopsy was the only marker to predict
evolution toward villous atrophy
Salmi (13) 40 years (16–81) 25 EMA+,
Marsh 0–1
12/12 SE: 93 – TG2 had the best SE and SP for
detecting early developing CDSP: 93
Maglio (17) 6 years, 4 months
(6 months–16 years)
109 TTG+, Marsh
0–1
74/109 SE: 67.9
SP: 87.9
Intensity
significantly
weaker in PCD
compared to CD
–
Tosco (19) 7 years (2–17) 28 TTG+, Marsh
0–1
19/28 SE: 68 – –
SP: 80
Kurppa (20) 11 years (4–17) 17 EMA+,
Marsh 0–2
17/17 SE: 100 Less intense in
PCD than CD
Seven of eight on a GCD develop
overt CD within 2 yearsSP: 100
Tosco (30) 7 years, 1 month
(9 months–17 years,
11 months)
39 EMA or
TTG+, normal
histology
33/39 SE: 85
SP: 91
– –
SE, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; EMA, anti-endomysium antibodies;TTG, anti-transglutaminase antibodies;
PCD, potential CD; ne, not evaluable (no control group).
while 20 (95%) had deposits in the SB mucosa (24). In addition,
the intensity of deposits has been shown to gradually decrease
during the GFD (14, 15).
Intestinal deposits were also investigated as an early marker
of intestinal damage after gluten-exposure. In an interventional
study, Koskinen et al. analyzed 23 CD children in clinical, serolog-
ical, and histological remission, 13 were randomized to undergo
an open oats challenge and 10 a gluten-challenge (GC) for 2 years.
At baseline, weak-to-moderate TG2 IgA deposits were present in 4
of 13 in the oat challenge group and in 3 of 10 in the GC group. In
the oats group, there was no significant change in the intensity of
the deposits within 2 years, while in the gluten group the intensity
of the deposits clearly increased and decreased again on a GFD.
The intensity of deposits correlated well with serum TG2-antibody
levels and the severity of SB mucosal villous damage (23).
In another study by Kaukinen et al., 41 adults with suspected
CD (increased density of mucosal γδ+ IELs but normal villous
morphology) were randomized to GFD or GC for a 6 months
period. Using a clinical score, 11 out of 41 patients were defined
as having a gluten-related disorder (5 in the GC and 6 in GFD
group). In this subgroup, TG2 deposits were positive in 10 out of
11 and intensity increased upon GC and again decreased on GFD.
Conversely IgA deposits were present in only 3 out of 30 patients
with suspected CD with no clinical signs of gluten-sensitivity (16).
INTESTINAL DEPOSITS IN OTHER GLUTEN-RELATED DISORDERS,
AUTOIMMUNE CONDITIONS, AND IgA DEFICIENCY
A few studies investigated the prevalence and significance of
intestinal deposits in other gluten-related disorders. In subjects
with DH, the presence of cutaneous IgA deposits directed against
TG3, as a marker of the disease, is well-established. The first study
by Karponay-Szabò et al. investigating the presence of intestinal
deposits in CD also enrolled 11 patients with DH (8). TG2 deposits
were present in seven of them (63%) who had a normal villous
architecture and two of them were negative for circulating EMA.
One single study specifically explored the intestinal TG2 deposits
in DH detecting them in 79% of untreated DH patients (with mod-
erate or severe intensity) and in 41% of GFD treated DH patients
(all with weak intensity). The presence and the intensity of the
deposits were strongly correlated with the degree of the intestinal
damage (25).
A small study (26) reported the presence of anti-TG2 intestinal
deposits in 100% of nine patients with GA, and the lack of TG2
deposits in a group of patients with other causes of ataxia and
positivity for serum AGA. Stenberg et al. failed to demonstrate
an increased prevalence of intestinal TG2 deposits in children
with cerebral palsy and elevated levels of CD-related sero-markers
(AGA or TTG). In this group of 16 patients, only 1 showed IgA co-
localizing with TG2 in the SB mucosa, suggesting CD at an early
stage (27).
Interestingly, a high percentage of children with T1D on a
normal diet presented with mucosal deposits, irrespective of the
presence of circulating TTG antibodies. TG2 intestinal deposits
were found in 78 and 58% of T1D children with circulating anti-
TTG or not, respectively. Authors further examined molecular
features of TG2 deposits, showing that only in the T1D group with
positivity of serum TTG, the TG2 deposits had the same mole-
cular characteristics found in CD-TG2 deposits. Particularly the
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serum-positive T1D patients showed a preferential involvement of
the heavy-chain variable region-5 (VH5) antibody gene family, as
well as in CD patients (28). In another study by Tosco et al., 20
T1D patients were enrolled as a control group and TG2 deposits
were detected in 5 of them (25%) (19).
The presence of intestinal deposits was also investigated in CD
children with IgA deficiency. For this purpose, immunofluores-
cence analysis of IgM anti-TG2 deposits in the SB biopsy of 25
CD children with IgA deficiency, 12 untreated CD with normal
IgA levels, 9 PCD with IgA deficiency, and 16 healthy controls
was described by Borrelli et al. Intestinal IgM deposits were more
prevalent in subjects with CD compared to PCD, but did not
discriminate accurately CD from PCD in this group with IgA
deficiency (29).
INTESTINAL DEPOSITS IN CONTROL GROUPS
Overall, 17 studies included a control group, all of them included
patients with negative CD sero-markers, that underwent SB biopsy
for GI disorders or other symptoms. The final diagnosis of these
patients were functional dyspepsia, irritable bowel syndrome,
gastro-esophageal reflux disease, multiple food intolerance, cow’s
milk allergy, IBD, iron deficiency anemia, failure to thrive, recur-
rent abdominal pain, dyspepsia, and T1D. Ten studies did not find
intestinal TG2 IgA deposits in the control group (8, 12, 16, 18,
20, 21, 24, 26, 29, 30). Conversely, six studies detected TG2 IgA
deposits in a minority of control subjects with a prevalence rang-
ing from 5 to 20%. Tosco et al. found that 3/34 (8.8%) children
with normal villous morphology presented TG2 IgA deposits (22).
Maglio et al. identified TG2 IgA deposits with a patchy distribution
and weak intensity in 11/91 (12%) children, among these 77% had
normal mucosa (Marsh 0, 1) whilst 23% had SB mucosa classified
as Marsh 3a, but no serological evidence of CD (17). Tosco et al.
enrolled 39 control children, of whom 20 had T1D. Deposits were
positive in 6/30 (20%) with a patchy distribution and among these
5/6 had T1D (19). Maglio et al. reported on 28 control patients
without CD. Among these, 4/28 (14.2%) had TG2 IgA deposits,
of whom 3 were affected with IBD (28). Koskinen et al. described
the presence of deposits in adult controls in 14/78 (18%) with a
weak, often patchy distribution (14). In another study, the same
authors enrolled 42 control patients with suspicion of CD but no
evidence of villous atrophy in two consecutive biopsy samples.
HLA DQ2 or DQ8 were present in 19/42 and 4 patients presented
CD serum antibodies at the onset, therefore they have to be con-
sidered potential. TG2 IgA deposits were present initially in 1/22
(5%) and in 3/39 (8%) patients on a gluten containing diet in the
follow-up biopsy (15). In an in vitro study by Stenman et al. (31),
authors did not find EMA antibodies in organ culture supernatants
derived from non-CD biopsies, but they did not specifically search
intestinal deposits in the control group.
COMPARISON BETWEEN INTESTINAL DEPOSITS AND ANTIBODIES
SECRETED INTO THE CULTURE SUPERNATANT
Two studies compared the secretion and the deposition of TG2
antibodies at the intestinal level (19, 31). Tosco et al. compared the
detection of mucosal deposits to the measurement of antibodies
secreted into culture supernatant. In overt CD patients, either TG2
deposits or antibodies secretion in the supernatant (higher than
the cut-off value) were detectable in 100% of patients, with no dif-
ferences when samples were cultured with medium alone or after
24 h of P31–43 or peptic tryptic gliadin digest (PTG). In PCD, the
presence of deposits was 67% at baseline and 60 and 90% after 24 h
incubation with medium alone and P31–43 or PTG, respectively.
Conversely, 96.4% of PCD had IgA antibodies in the supernatant
higher than the cut-off (with medium alone) and 92% after 24 h
P31–43 or PTG in vitro stimulation. In controls, the baseline preva-
lence of deposits (20%) decrease after culture with medium (7%)
and increase after in vitro gluten stimulation (36%). In the same
group of controls, production of antibodies in the supernatant
was 7 and 5% after culture with medium and 24 h P31–43 or PTG
incubation. Therefore, authors found the measurement of anti-
TG2 in culture supernatants to be more sensitive and specific than
the detection of mucosal deposits to reveal mucosal production
of anti-TG2 antibodies in CD, showing a sensitivity of 97.5 ver-
sus 77.5% and a specificity of 92.3 versus 80% of anti-TG2 in
supernatant and mucosal deposits detection, respectively (19).
Stenman et al. demonstrated that only biopsies derived from
patients on a short-term GFD and still having positive intesti-
nal TG2 IgA deposits were able to secrete EMA into the culture
supernatant, and speculated that autoantibody secretion in organ
culture supernatant of biopsies from treated CD patients reflected
the presence of positive intestinal TG2 IgA deposits (31).
DISCUSSION
An extensive review of the literature indicates that intestinal
deposits of anti-TG2 IgA are detectable in almost all patients with
CD at diagnosis, the only exception being represented by children
younger than 2 years of age, where the sensibility of the test is
73%. This data may simply reflect the natural fluctuation of these
autoantibodies in serum as previously observed (6). The speci-
ficity of this tool varies from 80 to 100% at diagnosis. Control
groups were found to show deposits in 5–20% of cases, with the
highest prevalence being described in T1D and IBD patients. Both
these conditions are well-known autoimmune disorders, charac-
terized by an important role of an environmental component
and frequent finding of CD serological markers. Therefore, the
presence of intestinal deposits is not entirely surprising in these
conditions, and suggests a possible role of gluten as a disease
trigger.
No studies specifically investigated the correlation between the
presence of intestinal deposits and the clinical presentation of
CD. This would be particularly important in the context of the
new ESPGHAN diagnostic criteria for CD. According to the new
European criteria (33), diagnosis of CD in patients with a classi-
cal clinical picture, high antibody titer, and HLA predisposition
does not require a SB biopsy. Conversely, children with no clinical
symptoms and/or low titer antibodies still need the SB biopsy. In
this subgroup of patients, the validation of a further histological
marker, i.e., the intestinal TG2 deposits, could be useful.
Results from follow-up studies show that the intestinal deposits
slowly disappear after starting treatment with the GFD. In com-
parison with the serological markers, intestinal deposits tend to
disappear later, being still detectable in 56% of patients after many
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years of GFD (2–42 years). In the same individuals, serological
markers were positive only in 15% of patients. Factors influencing
the persistence of IgA deposits have not been specifically investi-
gated, particularly we did not find studies correlating the presence
of deposits with the adherence to the diet. However, it is interest-
ing to note that the deposits were frequently detectable in a large
proportion of patients with non-responsive CD reporting good
adherence to the GFD, indicating that in this context their pres-
ence may reflect the celiac inflammatory process and not simply
the gluten consumption.
Overall few data are available on the possible role of TG2
deposits as an early marker of gluten-exposure during a GC,
therefore no conclusion can be drawn on this issue. To test their
performance in detecting gluten effects at the intestinal level in
CD patients, results from interventional and specifically designed
studies (both in vitro and in vivo) are warranted.
As a marker of early damage in PCD, TG2 deposits were found
in a high percentage of patients of all ages at first biopsy, ranging
from 68 to 100% of cases. Unfortunately, there are no prospec-
tive studies specifically designed to test the sensitivity of intestinal
deposits in predicting the development of villous atrophy. Data
from a pediatric case-series (39 re-biopsied PCD children) seem
to indicate that the finding of TG2 deposits at first observation is
a risk factor for developing CD, but these data have never been
replicated in larger studies and with a longer period of follow-up.
Their application as a predictive tool in PCD continues to be an
appealing but still not clearly defined option. In comparison with
other methods of intestinal antibodies detection, TG2 deposits
were found to be less sensitive and specific than the measurement
of anti-TG2 in culture supernatants in PCD at diagnosis (19).
Measurement of intestinal antibodies in the culture supernatant
is an easier technique, compared to TG2 deposits, and, being an
ELISA test, is less influenced by the operator’s ability. Therefore
the pros and cons of these two promising tools need to be com-
pared in prospective studies, aiming to characterize the precise role
of intestinal antibodies (production and deposition) in predicting
villous atrophy.
The TG2 deposits technique has also been used in non-CD
conditions, such as other gluten-related disorders and autoim-
mune conditions. A very high percentage of patients with DH and
the totality of a small group with GA showed deposition of TG2
antibodies at the intestinal level. Data from T1D patients are puz-
zling, considering that 78 and 58% of T1D patients (serologically
TG2 positive and negative, respectively) expressed TG2 deposits
at the intestinal level. In T1D patients, a transient positivity of
serological CD marker is frequently described at diagnosis (34).
It is interesting to note that only TG2 deposits in T1D patients
with positive serum TTG had the same molecular features of
CD deposits. Therefore, it is not clear whether the presence of
deposits is a further confirmation of a possible role of gluten in
T1D development or is an unspecific autoimmune phenomenon
in this group of patients.
It is a limitation of this review that a large proportion of the
available data on intestinal deposits come from studies performed
by two single European groups, in a relatively short period of time.
Confirmation of these results is awaited from other groups and in
different settings.
CONCLUSION
TG2 deposits are an appealing diagnostic tool, particularly in the
setting of challenging CD diagnosis and refractory CD. The value
as a prognostic marker in early stage CD has not clearly been estab-
lished. Overall, the costs and benefits of performing this test need
to be very well balanced, considering the technical difficulties and
the high costs of the exam.
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